ESLA
Price
$1.18
Change
+$0.01 (+0.85%)
Updated
Jan 17 closing price
Capitalization
42.69M
FATE
Price
$1.27
Change
+$0.02 (+1.60%)
Updated
Jan 17 closing price
Capitalization
144.65M
43 days until earnings call
Ad is loading...

ESLA vs FATE

Header iconESLA vs FATE Comparison
Open Charts ESLA vs FATEBanner chart's image
Estrella Immunopharma
Price$1.18
Change+$0.01 (+0.85%)
Volume$8.88K
Capitalization42.69M
Fate Therapeutics
Price$1.27
Change+$0.02 (+1.60%)
Volume$1.27M
Capitalization144.65M
ESLA vs FATE Comparison Chart
Loading...
ESLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ESLA vs. FATE commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESLA is a Hold and FATE is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (ESLA: $1.18 vs. FATE: $1.27)
Brand notoriety: ESLA and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ESLA: 25% vs. FATE: 32%
Market capitalization -- ESLA: $42.69M vs. FATE: $144.65M
ESLA [@Biotechnology] is valued at $42.69M. FATE’s [@Biotechnology] market capitalization is $144.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESLA’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ESLA’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both ESLA and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESLA’s TA Score shows that 1 TA indicator(s) are bullish while FATE’s TA Score has 3 bullish TA indicator(s).

  • ESLA’s TA Score: 1 bullish, 2 bearish.
  • FATE’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, FATE is a better buy in the short-term than ESLA.

Price Growth

ESLA (@Biotechnology) experienced а -0.84% price change this week, while FATE (@Biotechnology) price change was -13.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

ESLA is expected to report earnings on Mar 14, 2023.

FATE is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($145M) has a higher market cap than ESLA($42.7M). ESLA YTD gains are higher at: -1.667 vs. FATE (-23.030). ESLA has higher annual earnings (EBITDA): -8.82M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. ESLA (1.8M). FATE has higher revenues than ESLA: FATE (13.4M) vs ESLA (0).
ESLAFATEESLA / FATE
Capitalization42.7M145M29%
EBITDA-8.82M-177.57M5%
Gain YTD-1.667-23.0307%
P/E RatioN/AN/A-
Revenue013.4M-
Total Cash1.8M297M1%
Total DebtN/A99M-
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
72
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
96
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ESLAFATE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 11 days ago
59%
Bearish Trend 11 days ago
89%
Momentum
ODDS (%)
Bearish Trend 11 days ago
48%
Bullish Trend 11 days ago
82%
MACD
ODDS (%)
N/A
Bullish Trend 11 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
60%
Bullish Trend 11 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
69%
Bearish Trend 11 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 13 days ago
86%
Declines
ODDS (%)
Bearish Trend 17 days ago
84%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 11 days ago
90%
View a ticker or compare two or three
Ad is loading...
ESLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HMY9.770.31
+3.28%
Harmony Gold Mining Company Limited
CLMB130.173.21
+2.53%
Climb Global Solutions
RPID1.230.03
+2.50%
Rapid Micro Biosystems
BUSE23.130.27
+1.18%
First Busey Corp
ROST149.150.15
+0.10%
Ross Stores

ESLA and

Correlation & Price change

A.I.dvisor tells us that ESLA and WINT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESLA and WINT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESLA
1D Price
Change %
ESLA100%
+0.68%
WINT - ESLA
29%
Poorly correlated
-3.44%
CYTOF - ESLA
23%
Poorly correlated
+20.00%
FATE - ESLA
23%
Poorly correlated
+1.60%
CMND - ESLA
23%
Poorly correlated
-1.97%
NRXS - ESLA
22%
Poorly correlated
+11.33%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+1.60%
ALLO - FATE
59%
Loosely correlated
-1.09%
RCKT - FATE
52%
Loosely correlated
+0.98%
CRSP - FATE
51%
Loosely correlated
+0.57%
CRBU - FATE
50%
Loosely correlated
-0.65%
PRME - FATE
50%
Loosely correlated
+0.70%
More